Navigation Links
Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements

Research conducted by retina surgeons at The Methodist Hospital shows unprecedented improvements in vision in more than one-third of patients treated with Lucentis? for wet// age-related macular degeneration (AMD), according to findings published today in the New England Journal of Medicine. AMD is a major cause of central visual loss and is one of the leading causes of blindness in people over 60.

Dr. David M. Brown, retinal surgeon with Vitreoretinal Consultants at The Methodist Hospital, is lead author on the ANCHOR study and a secondary author on the MARINA study. Brown enrolled more patients than any other site worldwide in the studies, which contributed to the U.S. Food and Drug Administration’s June approval of Lucentis for the treatment of patients with wet AMD.

“Lucentis therapy is the most significant advance in the treatment of macular degeneration in the history of the disease,” said Brown. “The ANCHOR study compared the previous treatment for macular degeneration (photodynamic therapy) with Lucentis in the most aggressive form of the disease. While 60 percent of the eyes treated with photodynamic therapy were legally blind at the end of the first year of study, patients who received Lucentis treatment were able to avoid legal blindness in seven out of eight cases. Seven percent of the Lucentis-treated patients improved to 20/20 vision at the one year endpoint. It truly made a remarkable difference in many of these patient’s lives enabling them to maintain driving and keep their independence.”

Data from the two randomized, controlled pivotal Phase III clinical trials of Lucentis (ranibizumab injection) shows that at one year, 95 percent of patients treated with Lucentis did not lose vision. Of these patients, 55 percent maintained their vision (defined as a loss of less than 15 letters in visual acuity) and up to 40 percent experienced an improvement of three lines (15 letters) or more on the study eye chart. In the MA RINA study, patients were randomized to receive Lucentis injections once a month for two years. Patients in the ANCHOR study were randomized to either receive Lucentis injections once a month or photodynamic therapy every three months for two years.

Lucentis is designed to block new blood vessel growth and leakiness, which lead to wet AMD, by binding to and inhibiting VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels. Wet AMD affects the macula, the portion of the eye responsible for the central vision required for everyday activities such as reading, driving and recognizing faces. Symptoms include blurred, gray or blank spots in the center of the visual field and distortion that makes edges or lines appear wavy.

The National Eye Institute estimates that there are 1.7 million people with the advanced form of AMD in the United States and that this prevalence will grow to 2.95 million by 2020.

AMD occurs in two forms: dry and wet. While all cases begin as the dry form, wet AMD accounts for about 85 percent of all AMD-related blindness and can result in sudden and severe vision loss. The dry form is associated with atrophic cell death of the central retina or macula. The wet form is caused by growth of abnormal blood vessels that leak fluid and blood under the macula causing scar tissue that destroys the central retina.

Source-NewswiseSRM
'"/>




Related medicine news :

1. Hormone Deficiency Results In Miscarriage
2. Breast Implants May Interfere With The Interpretation Of Mammogram Results
3. DNA Testing For More Accurate Results
4. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
5. Intense Fight Against Polio In India Gets Results
6. Deadly Diarrhoea Vaccine – Trail Results Promising
7. Novartis MS Drug Shows Promising Results
8. Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today
9. Dealing With Stress Results In Better Academic Performance
10. Excess Intake of Alcohol Results in Permanent DNA Damage.
11. Study Reveals Better Results in Patients Suffering From Depression.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... May 31, 2016 , ... In his latest video, ... traits in humans. Using presidential candidate Donald Trump as an example, Kalsi describes ... “AstroNumerology is not about adding numbers up,” says Kalsi. “It is about looking ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta ... of New Jersey in the class of 1986, where he graduated in the top ... his current location in Livingston since 1989. He has been a member in good ...
(Date:5/31/2016)... ... ... Super Powder, a supplement produced by Prox Formulas for providing protein ... to transform the nutritional supplement industry by providing a safe, natural approach to enhanced ... (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit A, B1, ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts on June ... summer camp offers families and children a fun and unique experience with an ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: